Biogen slashes price of controversial Alzheimer's drug

After a slow start for its Alzheimer's treatment, Aduhelm, US-based Biogen is attempting to kick-start sales by halving the price.

Photo: BRIAN SNYDER/REUTERS / X90051

by marketwire, translated by catherine brett

Published: 20.12.21 at 13:59

US-based Biogen has dropped the price of its Alzheimer's treatment Aduhelm by fifty percent, Bloomberg News reports.

This has happened to light a fire under the sales, which have stagnated since the product's launch, partially because of its high price tag.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

Access all locked articles
Receive our daily newsletters
Access our app

Start a free company trial today

More from MedWatch

GN purchase story is very speculative, says analyst

Foto: GN Store Nord / PR

Competition rules could block a purchase of GN Store Nord and subsequent divestment of GN Hearing, says a Sydbank analyst on the speculative story that this might be underway.

Novo Nordisk invests additional millions of dollars in new manufacturing facilities

Foto: Novo Nordisk / PR

Novo Nordisk’s DKK 17bn (USD 2.4bn) investment into upgrading and building new facilities in Kalundborg last year has now been followed by a DKK 1bn (USD 143.8m) investment in the same location.

CHMP to remove 100 generic medicines from market

Foto: Russell Cheyne/Reuters/Ritzau Scanpix

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Germany orders 40,000 monkeypox vaccines from Bavarian Nordic

Foto: Elizabeth Dalziel/AP/Ritzau Scanpix

The German Minister for Health has revealed that the German state has ordered vaccines from Bavarian Nordic, as the country reports 5 cases of monkeypox.

New head of research at Astellas Gene Therapies: "Choosing the right indications is extra important"

Morten Søgaard is moving from one US coast to another, as he makes a switch from Pfizer to Astellas Gene Therapies | Foto: Jens Panduro

Morten Søgaard is leaving Pfizer to join Astellas, where he will be in charge of 100 employees. Going from one of the world largest pharmaceutical firms to a considerably smaller one will be a challenge, he says.

Further reading

Related articles